Literature DB >> 17198308

New transcription factors in diagnostic hematopathology.

Maurilio Ponzoni1, Gianluigi Arrigoni, Claudio Doglioni.   

Abstract

The transcription factors (TFs) that controls the intricate machinery of multistep differentiation and activation programs of the lymphoid system, represent a complex array of proteins, whose identification and function has only in part been completed. TFs are usually expressed during specific differentiation or activation cellular programs, making them interesting tools in diagnostic immunohistochemistry. In fact, the specificity of some of these TFs for lineage or activation/differentiation passages or their abnormal expression in specific disease entity, represents a feature that has been exploited in diagnostic/prognostic immunohistochemistry. Bcl-6 was the prototype of this class of markers. Currently, the expanding knowledge of the TFs involved in the differentiation programs and in the activation processes of T-lymphocyte and B-lymphocyte in normal and neoplastic conditions and the availability of antibodies able to efficiently recognize these TFs in histologic material, represent a powerful tool in diagnostic hematopathology. In this review we will consider the basic biologic aspects and the applications in hematopathology of some of the lymphocyte-related TFs, including Pax5/BSAB, MUM1/IRF4, BOB1, Oct-2, T-bet, and FOXP3. This field is rapidly evolving, as witnessed by the ongoing growing number of novel TFs with possible diagnostic applications appearing in the literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198308     DOI: 10.1097/PAP.0b013e31802f0495

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  5 in total

1.  Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.

Authors:  F A Batista; L S Ward; M A Marcello; M B Martins; K C Peres; C Torricelli; N E Bufalo; F A Soares; M J da Silva; L V M Assumpção
Journal:  J Endocrinol Invest       Date:  2015-09-14       Impact factor: 4.256

2.  Lymphocyte-depleted classic Hodgkin lymphoma-a neglected entity?

Authors:  Daniel Benharroch; Amalia Levy; Jacob Gopas; Martin Sacks
Journal:  Virchows Arch       Date:  2008-10-29       Impact factor: 4.064

3.  Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.

Authors:  Gabriela Gualco; Eduardo M Queiroga; Lawrence M Weiss; Claudete E N Klumb; William J Harrington; Carlos E Bacchi
Journal:  Hum Pathol       Date:  2009-01-13       Impact factor: 3.466

4.  CRX is a diagnostic marker of retinal and pineal lineage tumors.

Authors:  Sandro Santagata; Cecile L Maire; Ahmed Idbaih; Lars Geffers; Mick Correll; Kristina Holton; John Quackenbush; Keith L Ligon
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

5.  Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk.

Authors:  Sophia S Wang; Mark P Purdue; James R Cerhan; Tongzhang Zheng; Idan Menashe; Bruce K Armstrong; Qing Lan; Patricia Hartge; Anne Kricker; Yawei Zhang; Lindsay M Morton; Claire M Vajdic; Theodore R Holford; Richard K Severson; Andrew Grulich; Brian P Leaderer; Scott Davis; Wendy Cozen; Meredith Yeager; Stephen J Chanock; Nilanjan Chatterjee; Nathaniel Rothman
Journal:  PLoS One       Date:  2009-04-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.